ORGANIC
LETTERS
2013
Vol. 15, No. 21
5448–5451
Concise Copper-Catalyzed Synthesis
of Tricyclic Biaryl Ether-Linked
Aza-Heterocyclic Ring Systems
Paola Mestichelli,† Matthew J. Scott,† Warren R. J. D. Galloway,† Jamie Selwyn,†
Jeremy S. Parker,‡ and David R. Spring*,†
Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2
1EW, U.K., and AstraZeneca, Pharmaceutical Development, Charter Way,
Silk Road Business Park, Macclesfield, Cheshire SK10 2NA, U.K.
Received September 5, 2013
ABSTRACT
A new method for the synthesis of tricyclic biaryl ether-linked ring systems incorporating seven-, eight-, and nine-membered ring amines is presented. In
the presence of catalytic quantities of copper(I), readily accessible acyclic precursors undergo an intramolecular carbonÀoxygen bond-forming reaction
facilitated by a “templating” chelating nitrogen atom. The methodology displays a broad substrate scope, is practical, and generates rare and biologically
interesting tricyclic heteroaromatic products that are difficult to access by other means.
Tricyclic aza-hetereocyclic ring systems incorporating
a biaryl ether motif are present in a number of biologically
active and pharmaceutically relevant compounds and thus
constitute very attractive synthetic targets. For example,
the dibenzooxazepinones1 and dibenzooxazepines2 have
been shown to exhibit significant biological activities
(Figure 1). The dibenz[b,g][1,5]oxazocines, which contain
a tricyclic biaryl ether-linked ring system incorporating
an eight-membered ring amine, are comparatively much
less well studied, but some are known to be CNS active and
are used for the treatment of pain and/or inflammation.3
Despite these interesting biological properties, examples
are relatively rare; analogous compounds containing
seven- and nine-membered amine ring systems are extremely
scarce. Consequently, compounds of this sort (indeed, seven-
nine membered cyclic biaryl ethers in general) are under-
represented in current small molecule screening libraries.
This can mainly be attributed to synthetic difficulties; for
example, there are notable problems associated with medium
ring synthesis, with medium ring biaryl scaffolds representing
especially challenging targets.4,5 Overall, there are a lack of
† University of Cambridge.
‡ AstraZeneca, Pharmaceutical Development.
(1) For examples, see: (a) Wang, L.; Sullivan, G. M.; Hexamer, L. A.;
Hasvold, L. A.; Thalji, R.; Przytulinska, M.; Tao, Z.; Li, G.; Chen, Z.;
Xiao, Z.; Gu, W.; Xue, J.; Bui, M.; Merta, P.; Kovar, P.; Bouska, J. J.;
Zhang, H.; Park, C.; Stewart, K. D.; Sham, H. L.; Sowin, T. J.;
Rosenberg, S. H.; Lin, N. J. Med. Chem. 2007, 50, 4162. (b) Klunder,
J. M.; Hargrave, K. D.; West, M.; Cullen, E.; Pal, K.; Behnke, M. L.;
Kapadia, S. R.; McNeil, D. W.; Wu, J. C.; Chow, G. C. J. Med. Chem.
1992, 35, 1887. (c) Lu, S. M.; Maggi, C. A.; Gensini, M.; Bigioni, M.;
Parlani, M.; Giolitti, A.; Fratelli, M.; Valli, C.; Terao, M.; Garattini, E.
ACS Med. Chem. Lett. 2010, 1, 411. For Sintamil, see, for example: (d)
David, J.; Grewal, R. S. Indian J. Exp. Biol. 1974, 12, 225.
(2) For examples, see: (a) Jiang, X. L.; Lee, G. T.; Prasad, K.; Repic,
O. Org. Process Res. Dev. 2008, 12, 1137. (b) Sakaki, J.; Konishi, K.;
Kishida, M.; Gunji, H.; Kanazawa, T.; Uchiyama, H.; Fukaya, H.;
Mitani, H.; Kimura, M. Bioorg. Med. Chem. Lett. 2007, 17, 4808. (c)
Ebisawa, M.; Umemiya, H.; Ohta, K.; Fukasawa, H.; Kawachi, E.;
Christoffel, G.; Gronemeyer, H.; Tsuji, M.; Hashimoto, Y.; Shudo, K.;
Kagechika, H. Chem. Pharm. Bull 1999, 47, 1778. For Loxapine, see for
example: (d) Chakrabarti A.; Bagnall, A. M.; Chue, P.; Fenton, M.;
Palaniswamy, V.; Wong, W.; Xia, J. Loxapine for schizophrenia.
Cochrane Database of Systematic Reviews 2007, Issue 4, Art. No.
CD001943.
(3) (a) Ouyang, X.; Chen, Z.; Liu, L.; Dominguez, C.; Kiselyove,
A. S. Tetrahedron 2000, 56, 2369. (b) Ouyang, X.; Kiselyove, A. S.
Tetrahedron Lett. 1999, 40, 5827. See, for example: (c) Ohgog, T.;
Tanaka, S.; Fujimoto, M.; Kitahara, A. Yakugaku Zassi 1977, 97, 24.
(d) Tanaka, S.; Hashimoto, K. 6-substituierte 6,7-dihydro-5H-dibenzo
b.g. 1.5 Oxazocine und Thiazocine und Verfahren zu deren Herstellung.
Ger. Offen. DE 2044508, May 1971. (e) Joergensen, T. K.; Andersen, K. E.;
Andersen, H. S.; Hohlweg, R.; Madsen, P.; Olsen, U. B. Novel Heterocyclic
Compounds. WO 9631497 A1, October 1996.
r
10.1021/ol4025259
Published on Web 10/17/2013
2013 American Chemical Society